摩熵化学
数据库官网
小程序
打开微信扫一扫
首页 分子通 化学资讯 化学百科 反应查询 关于我们
请输入关键词

(9Z,12Z)-(7-hydroxy-6a-(hydroxymethyl)-4,4,11b-trimethyl-2,3,4,4a,5,6,6a,7,8,11,11a,11b-dodecahydro-1H-cyclohepta[a]naphthalene-9-yl)methyl octadeca-9,12,dienoate

中文名称
——
中文别名
——
英文名称
(9Z,12Z)-(7-hydroxy-6a-(hydroxymethyl)-4,4,11b-trimethyl-2,3,4,4a,5,6,6a,7,8,11,11a,11b-dodecahydro-1H-cyclohepta[a]naphthalene-9-yl)methyl octadeca-9,12,dienoate
英文别名
[7-hydroxy-6a-(hydroxymethyl)-4,4,11b-trimethyl-1,2,3,4a,5,6,7,8,11,11a-decahydrocyclohepta[a]naphthalen-9-yl]methyl (9Z,12Z)-octadeca-9,12-dienoate
(9Z,12Z)-(7-hydroxy-6a-(hydroxymethyl)-4,4,11b-trimethyl-2,3,4,4a,5,6,6a,7,8,11,11a,11b-dodecahydro-1H-cyclohepta[a]naphthalene-9-yl)methyl octadeca-9,12,dienoate化学式
CAS
——
化学式
C38H64O4
mdl
——
分子量
584.924
InChiKey
CQCCPGGDBICCBV-UTJQPWESSA-N
BEILSTEIN
——
EINECS
——
  • 物化性质
  • 计算性质
  • ADMET
  • 安全信息
  • SDS
  • 制备方法与用途
  • 上下游信息
  • 反应信息
  • 文献信息
  • 表征谱图
  • 同类化合物
  • 相关功能分类
  • 相关结构分类

计算性质

  • 辛醇/水分配系数(LogP):
    11.2
  • 重原子数:
    42
  • 可旋转键数:
    18
  • 环数:
    3.0
  • sp3杂化的碳原子比例:
    0.82
  • 拓扑面积:
    66.8
  • 氢给体数:
    2
  • 氢受体数:
    4

反应信息

  • 作为产物:
    描述:
    (Z,Z)-9,12-十八烷二烯酸二聚物 、 ((6aR,7R,11aR,11bS)-7-hydroxy-4,4,11b-trimethyl-2,3,4,4a,5,6,6a,7,8,11,11a,11b-dodecahydro-1H-cyclohepta[a]naphthalene-6a,9-diyl)dimethanol 在 4-二甲氨基吡啶N,N'-二环己基碳二亚胺 作用下, 以 二氯甲烷 为溶剂, 以40%的产率得到(9Z,12Z)-(7-hydroxy-6a-(hydroxymethyl)-4,4,11b-trimethyl-2,3,4,4a,5,6,6a,7,8,11,11a,11b-dodecahydro-1H-cyclohepta[a]naphthalene-9-yl)methyl octadeca-9,12,dienoate
    参考文献:
    名称:
    GLUCAGON-LIKE PEPTIDE 1 (GLP-1) RECEPTOR MODULATORS AND USES THEREOF IN REGULATING BLOOD GLUCOSE LEVELS
    摘要:
    本公开提供了新型胰高血糖素样肽-1(GLP-1)受体调节剂,例如式(I)或(II)的化合物,以及其药学上可接受的盐。本公开还提供了涉及GLP-1受体调节剂用于调节血糖水平和/或治疗糖尿病的药物组合物、试剂盒和用途。例如,通过调节由GLP-1受体介导的内源性信号通路。
    公开号:
    US20140350100A1
点击查看最新优质反应信息

文献信息

  • SYNTHESIS OF GALANAL COMPOUNDS AND ANALOGUES THEREOF
    申请人:Academia Sinica
    公开号:US20140350288A1
    公开(公告)日:2014-11-27
    The present disclosure provides methods of preparing glucagon-like peptide-1 (GLP-1) receptor modulators, such as compounds of Formula (II) or (VI), or intermediates thereof. The compounds that may be prepared by the described methods are useful for regulating blood glucose levels and/or treating a disease mediated by a GLP-1 receptor (e.g., diabetes).
  • US9193665B2
    申请人:——
    公开号:US9193665B2
    公开(公告)日:2015-11-24
  • [EN] GLUCAGON-LIKE PEPTIDE 1 (GLP-1) RECEPTOR MODULATORS AND USES THEREOF IN REGULATING BLOOD GLUCOSE LEVELS<br/>[FR] MODULATEURS DU RÉCEPTEUR DU GLUCAGON-LIKE PEPTIDE 1 (GLP-1) ET LEURS UTILISATIONS DANS LA RÉGULATION DES TAUX DE GLYCÉMIE
    申请人:ACADEMIA SINICA
    公开号:WO2014193832A2
    公开(公告)日:2014-12-04
    The present disclosure provides novel glucagon-like peptide-1 (GLP-1) receptor modulators such as compounds of Formula (I) or (II), and pharmaceutically acceptable salts thereof. The present disclosure also provides pharmaceutical compositions, kits, and uses that involve the GLP-1 receptor modulators for regulating blood glucose levels and/or treating diabetes via, e.g., modulating the endogenous signaling pathways mediated by the GLP-1 receptor.
  • [EN] SYNTHESIS OF GALANAL COMPOUNDS AND ANALOGUES THEREOF<br/>[FR] SYNTHÈSE DE COMPOSÉS DE GALANAL ET LEURS ANALOGUES
    申请人:ACADEMIA SINICA
    公开号:WO2014193837A1
    公开(公告)日:2014-12-04
    The present disclosure provides methods of preparing glucagon-like peptide-1 (GLP-1) receptor modulators, such as compounds of Formula (II) or (VI), or intermediates thereof. The compounds that may be prepared by the described methods are useful for regulating blood glucose levels and/or treating a disease mediated by a GLP-1 receptor (e.g.diabetes).
  • GLUCAGON-LIKE PEPTIDE 1 (GLP-1) RECEPTOR MODULATORS AND USES THEREOF IN REGULATING BLOOD GLUCOSE LEVELS
    申请人:Liang Chi-Ming
    公开号:US20140350100A1
    公开(公告)日:2014-11-27
    The present disclosure provides novel glucagon-like peptide-1 (GLP-1) receptor modulators such as compounds of Formula (I) or (II), and pharmaceutically acceptable salts thereof. The present disclosure also provides pharmaceutical compositions, kits, and uses that involve the GLP-1 receptor modulators for regulating blood glucose levels and/or treating diabetes via, e.g., modulating the endogenous signaling pathways mediated by the GLP-1 receptor.
    本公开提供了新型胰高血糖素样肽-1(GLP-1)受体调节剂,例如式(I)或(II)的化合物,以及其药学上可接受的盐。本公开还提供了涉及GLP-1受体调节剂用于调节血糖水平和/或治疗糖尿病的药物组合物、试剂盒和用途。例如,通过调节由GLP-1受体介导的内源性信号通路。
查看更多